|Bid||5.96 x 2900|
|Ask||6.39 x 1800|
|Day's Range||5.83 - 6.67|
|52 Week Range||3.00 - 17.19|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Autolus Therapeutics (NASDAQ:AUTL) announces its next round of earnings this Thursday, March 04. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement. What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Autolus Therapeutics's per-share loss will be near $0.77 on sales of $340.00 thousand, according to Wall Street analysts. In the same quarter last year, Autolus Therapeutics reported a loss per share of $0.93 on sales of $309.00 thousand. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values. View more earnings on AUTL If the company were to report earnings in line when it publishes results Thursday, earnings would be up 17.2%. Revenue would be up 10.03% from the same quarter last year. Here is how the company's reported EPS has stacked up against analyst estimates in the past: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate -0.71 -0.71 -0.74 -0.74 EPS Actual -0.72 -0.62 -0.60 -0.93 Revenue Estimate 300.00 K 440.00 K 600.00 K 520.00 K Revenue Actual 680.00 K 293.00 K 338.00 K 309.00 K Stock Performance Shares of Autolus Therapeutics were trading at $6.8 as of March 02. Over the last 52-week period, shares are down 25.54%. Given that these returns are generally negative, long-term shareholders are probably unhappy going into this earnings release. Do not be surprised to see the stock move on comments made during its conference call. Autolus Therapeutics is scheduled to hold the call at 08:30:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaFirst Eagle Alternative's Earnings OutlookPreview: Purple Innovation's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for total gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 2.1 million ADSs. The offering is expected to close on February 12. J.P. Morgan and Wells Fargo Securities are acting as joint book-runners for the offering. Autolus did not mention the use for the proceeds raised. Still, last month, it prioritized the development of AUTO1 and thus planned to cut headcount by approximately 20% resulting in annualized savings of $15 million. AUTO1 is under development for adult acute lymphoblastic leukemia, with full data from the AUTO1-AL1 study expected in 2022. Autolus plans to seek a partner for the AUTO3 program, its CAR T product candidate for relapsed/refractory diffuse large B cell lymphoma, ahead of progressing into the next phase of development. Price Action: AUTL slid 2% at $7.35 during the premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaIterum Therapeutics Presses Capital Raise Button To Support Potential Sulopenem Launch ActivitiesTakeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.